Heat Biologics, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey Wolf
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 627 DAVIS DRIVE, SUITE 400 Morrisville NC United States of America 27560
- IPO Date
- Jul 24, 2013
- CIK
- 0001476963
- Website
- heatbio.com
- Similar Companies
- Business
- Heat Biologics, Inc. (HTBX) develops immunotherapies focused on activating the immune system against cancer. The company offers a portfolio of product candidates including ImPACT therapy platform for antigen-specific immunotherapy; HS-110, a T cell-stimulating biologic targeting lung cancer; HS-130, an agonist biologic for solid tumors; and earlier-stage programs such as PTX-25, a fusion protein vaccine for infectious diseases and cancer. These therapies aim to induce durable immune responses through co-stimulation and antigen presentation technologies. Founded in 2007 and headquartered in Morrisville, North Carolina, Heat Biologics operates primarily in the United States with clinical trials conducted across North America and select international sites targeting oncology patients and healthcare providers in the biopharmaceutical sector. In recent developments within the last two years, the company has advanced its pipeline through Phase 2 trial initiations for HS-110 in combination regimens and explored strategic partnerships for co-development in immuno-oncology, alongside funding efforts to support ongoing R&D expansions.
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
Heat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
Heat Biologics Announces Planned Transfer to the NYSE American
Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax Treatment
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110
Heat Biologics To Bolster Presence In Biodefense Space With Elusys Acquisition
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats
Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Heat Biologics to Provide Corporate Update
Heat Biologics Is Starting To Run Away From Support Toward Resistance